{"id":2205,"date":"2026-06-09T14:00:00","date_gmt":"2026-06-09T17:00:00","guid":{"rendered":"https:\/\/sevenresiduosaude.com.br\/blog\/?p=2205"},"modified":"2026-06-09T14:00:00","modified_gmt":"2026-06-09T17:00:00","slug":"pgrss-clinica-medicina-cir-oncologica-subglote-laringectomia-traqueostomia-tlm-tors-brachy","status":"publish","type":"post","link":"https:\/\/sevenresiduosaude.com.br\/blog\/pgrss-clinica-medicina-cir-oncologica-subglote-laringectomia-traqueostomia-tlm-tors-brachy\/","title":{"rendered":"PGRSS subglote: laringec, TLM, TORS, brachy"},"content":{"rendered":"

A regula\u00e7\u00e3o brasileira de RSS \u00e9 frequentemente subaproveitada por gestores de cl\u00ednicas de cirurgia oncol\u00f3gica subglote que reduzem PGRSS a descarte de bisturi e gaze<\/strong>. Em 2026, h\u00e1 um cen\u00e1rio desafiador \u2014 cl\u00ednicas de cir oncol\u00f3gica subglote<\/strong> + carcinoma escamoso subgl\u00f3tico raro 1-5%<\/strong> + laringectomia total LT obrigat\u00f3ria subglote alto<\/strong> + TLM Trans-Oral Laser Microsurgery laser CO2<\/strong> + TORS Trans-Oral Robotic Surgery Da Vinci SP<\/strong> + brachy intersticial Iridium-192<\/strong> + traqueostomia definitiva p\u00f3s-LT<\/strong> geram fluxos heterog\u00eaneos de RSS Grupo A1 (carcinoma escamoso subglote + extens\u00e3o glote + traqueia cervical) + Grupo A4 (linfa cervical bilateral n\u00edvel VI paratraqueal + IV jugular inferior + mediastino superior) + Grupo C (Iridium-192 brachy + I-131 met\u00e1stase + Cobalt-60 backup) + Grupo E (perfuro bi\u00f3psia + ressectosc\u00f3pio Storz). A consequ\u00eancia \u00e9 a pr\u00e1tica de cl\u00ednicas que otimizam apenas para gaze cir\u00fargica<\/strong> + ignoram especificidades oncol\u00f3gicas + paratraqueal<\/strong> + subdimensionam TLM laser CO2<\/strong> + perdem rastreabilidade tumor subglote<\/strong>. A realidade \u00e9 exatamente o oposto. PGRSS subglote opera em 5 fluxos oncol\u00f3gicos<\/strong> \u2014 A1 (carcinoma escamoso subglote + extens\u00e3o glote + traqueia + adenoCa rar\u00edssimo + adenoide c\u00edstico), A4 (esvaziamento cervical paratraqueal n\u00edvel VI + jugular inferior IV + mediastino superior), C (Iridium-192 brachy + I-131 PRRT + Cobalt-60), E (perfuro bi\u00f3psia + microlaringoscopia direta + traqueoscopia r\u00edgida), TLM\/TORS (laser CO2 + Da Vinci SP single-port + microdebrider Medtronic XPS+Stryker Formula 180).<\/p>\n

Para o gestor que opera ou planeja cl\u00ednica de cir oncol\u00f3gica subglote, \u00e9 fundamental dimensionar PGRSS espec\u00edfico desde o in\u00edcio.<\/p>\n

Os 5 fluxos oncol\u00f3gicos subglote<\/h2>\n

Em uma opera\u00e7\u00e3o de qualquer porte, o PGRSS subglote tem 5 fluxos.<\/p>\n\n\n\n\n\n\n\n\n\n
Fluxo<\/th>\nVolume<\/th>\nFrequ\u00eancia<\/th>\nParticularidade<\/th>\n<\/tr>\n<\/thead>\n
A1 carcinoma escamoso<\/td>\n3-9 kg\/dia<\/td>\nDi\u00e1ria<\/td>\nSubglote+ext glote<\/td>\n<\/tr>\n
A4 paratraqueal+VI<\/td>\n3-8 kg\/dia<\/td>\nDi\u00e1ria<\/td>\nMediastino superior<\/td>\n<\/tr>\n
C Iridium-192+I-131<\/td>\n0,4-1,2 kg\/dia<\/td>\nP\u00f3s-procedimento<\/td>\nLDR\/HDR+CNEN<\/td>\n<\/tr>\n
E perfuro bi\u00f3psia<\/td>\n0,3-0,8 kg\/dia<\/td>\nDi\u00e1ria<\/td>\nMicrolaring+traqueo<\/td>\n<\/tr>\n
TLM\/TORS laser+robot<\/td>\n0,8-2,5 kg\/dia<\/td>\nDi\u00e1ria<\/td>\nCO2+Da Vinci SP<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

A soma t\u00edpica \u00e9 7,5-21,5 kg\/dia<\/strong> em cl\u00ednica cir oncol\u00f3gica subglote m\u00e9dia porte.<\/p>\n

A1 carcinoma escamoso subglote: o est\u00e1gio cir\u00fargico<\/h2>\n

A primeira camada do PGRSS subglote \u00e9 A1. Padr\u00e3o setorial inclui (a) carcinoma escamoso subglote<\/strong> com rar\u00edssimo 1-5% laringe + cricoide + 1\u00bas an\u00e9is traqueais + estendido glote 30-40% casos + acometimento bilateral; (b) laringectomia total LT obrigat\u00f3ria<\/strong> com remo\u00e7\u00e3o completa laringe + cartilagem cricoide + 2-3 an\u00e9is traqueais + tireoide ipsilateral + traqueostomia definitiva alta + ressec\u00e7\u00e3o em monobloco; (c) subs\u00edtio anat\u00f4mico subglote<\/strong> zona posterior cricoide + zona anterior membrana cricotireoidea + zona lateral parede lateral + extens\u00e3o craniocaudal cricoide-traqueia 1-3cm; (d) estadiamento TNM 8\u00aa edi\u00e7\u00e3o<\/strong> Tis carcinoma in situ + T1 limitado subglote mobilidade preservada + T2 invas\u00e3o glote + T3 fixa\u00e7\u00e3o corda vocal + T4 invade cartilagem\/extralaringe; (e) descarte sub-fluxos<\/strong> com pr\u00e9-pesagem + saco branco leitoso + identifica\u00e7\u00e3o A1+SUBGLOTE+TNM+CID C32.2 + lacre + rastreabilidade.<\/p>\n

Cl\u00ednica com A1 subglote madura garante margem R0<\/strong> + previne recidiva traqueal<\/strong> + otimiza traqueostomia definitiva<\/strong>. Como discutimos no post sobre supraglote<\/a>, A1 \u00e9 a base.<\/p>\n

A4 esvaziamento paratraqueal + mediastino superior: o est\u00e1gio metast\u00e1tico<\/h2>\n

A segunda camada \u00e9 A4 paratraqueal. Padr\u00e3o setorial inclui (a) esvaziamento cervical paratraqueal n\u00edvel VI<\/strong> com paratraqueal direito + esquerdo + pr\u00e9-traqueal Delphian + recurrencial XII; (b) esvaziamento jugular inferior IV<\/strong> com jugular omo-hioidea + supraclavicular + carot\u00eddeo III-IV + ECM esternocleidomastoide funcional; (c) mediastinoscopia + mediastino superior<\/strong> com mediastinoscopia Carlens cervical + ressec\u00e7\u00e3o LN paratraqueal mediastinal alto + Chamberlain + EBUS+EUS amostragem; (d) bi\u00f3psia LN sentinela subglote<\/strong> com Tc-99m + ICG verde indocianina + DSL Dynamic Sentinel experimental; (e) descarte esvaziamento<\/strong> com pe\u00e7a anatomopatol\u00f3gica + LN dissecados 12-25 padr\u00e3o ouro + sentinela radioativo Tc-99m + lacre vermelho + identifica\u00e7\u00e3o separada A4+n\u00edvel.<\/p>\n

Cl\u00ednica com A4 paratraqueal+mediastino madura detecta micromet\u00e1stase<\/strong> + previne progress\u00e3o regional+mediastinal<\/strong> + gerencia complica\u00e7\u00e3o chyloperitoneum<\/strong>. Conex\u00e3o com hospital especializado<\/a>.<\/p>\n

TLM laser CO2 + TORS Da Vinci SP + brachy Iridium-192: o est\u00e1gio minimamente invasivo<\/h2>\n

A terceira camada \u00e9 TLM+TORS+brachy. Padr\u00e3o setorial inclui (a) TLM Trans-Oral Laser Microsurgery<\/strong> com laser CO2 OmniGuide flexible fiber+UltraPulse Lumenis+Sharplan + microdebrider Medtronic XPS+Stryker Formula 180 + ressec\u00e7\u00e3o endosc\u00f3pica via via subgl\u00f3tica dif\u00edcil acesso requer TORS; (b) TORS Trans-Oral Robotic Surgery<\/strong> com Da Vinci SP single-port + Da Vinci Xi + Medtronic Hugo + flex\u00edvel camera 3D + EndoWrist + Harmonic Ace+ + LigaSure Maryland + acesso subglote complementar; (c) microlaringoscopia direta + traqueoscopia r\u00edgida<\/strong> suporte Lindholm Karl Storz + endosc\u00f3pio r\u00edgido 0\u00b0\/30\u00b0\/70\u00b0 Storz\/Olympus + traqueosc\u00f3pio Karl Storz\/Wolf 5-7mm; (d) braquiterapia intersticial Iridium-192<\/strong> subglote+traqueia cervical + LDR low dose rate + HDR high dose rate + after-loading remote + agulhas paralelas + template + dosimetria 3D ICRU-58 + CNEN-NN-3.05 sala blindada baritada; (e) descarte TLM\/TORS+brachy<\/strong> com pe\u00e7a ressecada microsc\u00f3pica + fragmento laser carbonizado + pe\u00e7a brachy radioativa Ir-192 decaimento 74d + IPEN\/CNEN.<\/p>\n

Cl\u00ednica com TLM+TORS+brachy madura escala minimamente invasivo<\/strong> + preserva voz residual via pr\u00f3tese fonat\u00f3ria<\/strong> + garante CNEN compliance<\/strong>. Conex\u00e3o com Iridium-192 brachy<\/a>.<\/p>\n

Tr\u00eas perfis de PGRSS por capacidade subglote<\/h2>\n

Cl\u00ednica subglote s\u00f3 A1.<\/strong> 1 fluxo. Custo mensal R$ 7.500-22.000<\/strong> mas perda de A4+C+E+TLM\/TORS.<\/p>\n

Cl\u00ednica subglote A1 + A4.<\/strong> 2 fluxos. Custo mensal R$ 16.000-42.000<\/strong>, captura cirurgia + paratraqueal.<\/p>\n

Cl\u00ednica subglote 5 fluxos completos.<\/strong> A1+A4+C+E+TLM\/TORS + integra\u00e7\u00e3o com servi\u00e7os hospitalares<\/a>. Custo mensal R$ 28.000-72.000<\/strong>, efic\u00e1cia 95%, ROI 800-2.400% via captura completa subglote.<\/p>\n

Os tr\u00eas erros que aparecem em cir oncol\u00f3gica subglote<\/h2>\n

O primeiro \u00e9 a subdimensionamento TLM laser CO2 fumo cir\u00fargico<\/strong>. Sem manejo aerossol+exaustor laminar+filtro HEPA+EPI N95 = risco exposi\u00e7\u00e3o profissional + zero biosseguran\u00e7a + viola\u00e7\u00e3o NR-32.<\/p>\n

O segundo \u00e9 a mistura A1 carcinoma + A4 paratraqueal<\/strong>. Confunde rastreabilidade tumor + impossibilita esvaziamento padronizado n\u00edvel VI+IV + risco subestadiamento.<\/p>\n

O terceiro \u00e9 a falta de protocolo traqueostomia definitiva p\u00f3s-LT<\/strong>. Sem rastreabilidade Shiley\/Portex\/Bivona + manejo cuidados+aspira\u00e7\u00e3o = risco aspira\u00e7\u00e3o + zero qualidade vida + risco depress\u00e3o p\u00f3s-cir.<\/p>\n

A regula\u00e7\u00e3o de PGRSS subglote no Brasil est\u00e1 em fase de moderniza\u00e7\u00e3o t\u00e9cnica acelerada com cir oncol\u00f3gica preservadora como prioridade. As institui\u00e7\u00f5es que estruturam fluxos completos desde o in\u00edcio \u2014 alinhadas com PGRSS cl\u00ednicas especializadas<\/a> \u2014 atravessam o crescimento sem solavanco. Para gestores que precisam alinhar com gest\u00e3o paralela industrial, o portal Seven Res\u00edduos sobre servi\u00e7os completos<\/a> traz a perspectiva integrada. A INCA C\u00e2ncer Laringe Subglote<\/a> \u00e9 refer\u00eancia t\u00e9cnica nacional.<\/p>\n

Solicite cota\u00e7\u00e3o PGRSS subglote 5 fluxos oncol\u00f3gicos<\/a><\/strong> \u2014 cap\u00edtulo dedicado a A1 carcinoma escamoso subglote+cricoide+an\u00e9is traqueais+laringec total LT obrigat\u00f3ria+ressec\u00e7\u00e3o monobloco+CID C32.2+TNM 8\u00aa, A4 paratraqueal n\u00edvel VI direito+esquerdo+pr\u00e9-traqueal Delphian+jugular inferior IV+mediastino superior+Carlens+EBUS+EUS+sentinela DSL Tc-99m, C Iridium-192 LDR\/HDR brachy subglote+I-131 PRRT met\u00e1stase+Cobalt-60 backup+CNEN-NN-3.05, E perfuro microlaringoscopia direta+traqueoscopia r\u00edgida Storz\/Wolf 5-7mm, TLM laser CO2 OmniGuide+UltraPulse Lumenis+Sharplan+microdebrider Medtronic XPS+Stryker Formula 180+TORS Da Vinci SP+Xi+Medtronic Hugo+EndoWrist+Harmonic+LigaSure.<\/p>\n","protected":false},"excerpt":{"rendered":"

PGRSS oncologia subglote: laringec + TLM + TORS + brachy. Veja.<\/p>\n","protected":false},"author":3,"featured_media":2204,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[2712,2821,3037,2559],"class_list":["post-2205","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-compliance-legislacao","tag-cirurgia-oncologica","tag-laringectomia","tag-subglote","tag-tors"],"_links":{"self":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/2205","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/comments?post=2205"}],"version-history":[{"count":1,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/2205\/revisions"}],"predecessor-version":[{"id":4326,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/2205\/revisions\/4326"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/media\/2204"}],"wp:attachment":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/media?parent=2205"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/categories?post=2205"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/tags?post=2205"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}